Description
Product Overview: Tesamorelin
Tesamorelin is a synthetic 44-amino acid peptide analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH 1-44), stabilized by the addition of a trans-3-hexenoic acid group at its N-terminus. This structural modification enhances its resistance to enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), significantly extending its metabolic half-life. Tesamorelin selectively binds to and activates GHRH receptors on pituitary somatotrophs, driving the pulsatile synthesis and release of endogenous Growth Hormone (GH). It serves as a primary research compound for investigating visceral adiposity reduction, hepatic lipid metabolism, and neurocognitive signaling.
Primary Research Applications & Reasons for Study
- Visceral Adipose Tissue (VAT) Reduction: Upregulating lipolysis specifically in deep visceral fat depots via GH-induced triglyceride breakdown into free fatty acids and glycerol.
- Hepatic Steatosis & NAFLD/NASH Models: Investigating the clearance of intrahepatic triglyceride accumulation and reduction of liver inflammation/fibrosis markers.
- Pituitary GHRH Receptor Kinetics: Assessing somatotroph receptor binding affinity, cAMP intracellular activation, and downstream hepatic IGF-1 synthesis under DPP-4-resistant conditions.
- Cognitive Function & Neuroprotection: Studying central nervous system GHRH pathways, gamma-aminobutyric acid (GABA) modulation, and executive cognitive performance in aging models.
Expected Research Results & Timeline Metrics
-
Phase 1 / Minutes 30–90
Acute Endogenous GH Pulse: Rapid activation of somatotroph GHRH receptors drives a robust surge in circulating Growth Hormone levels, peaking within ~1 hour. -
Phase 2 / Weeks 2–4
IGF-1 Elevation & Initial Lipolysis: Statistically significant increases in circulating serum IGF-1 levels alongside early reductions in trunk/abdominal fat thickness. -
Phase 3 / Weeks 12–26
Targeted VAT Clearance & Hepatic Health: Up to ~15–18% reduction in visceral fat volume, measurable decreases in intrahepatic lipid content, and preserved glucose metabolism parameters.
Key Research Benefits
- DPP-4 Enzymatic Resistance: N-terminal hexenoic acid modification prevents rapid degradation, ensuring higher bioavailability and sustained action over native GHRH.
- Targeted Visceral Lipolysis: Selectively reduces deep abdominal fat without causing significant depletion of subcutaneous adipose tissue or lean muscle mass.
- Physiological Feedback Preservation: Stimulates natural, pulsatile GH release while respecting somatostatin feedback control mechanisms to prevent hyper-somatotropism.
- Favorable Metabolic Profile: Promotes adipose breakdown without negatively impacting baseline insulin sensitivity or glucose tolerance in research models.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.